Literature DB >> 28188614

Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas.

Rémy Bonnavion1,2,3, Romain Teinturier1,2,3, Samuele Gherardi1,2,3, Emmanuelle Leteurtre4,5, Run Yu6, Martine Cordier-Bussat1,2,3, Rui Du7,8, François Pattou5,9, Marie-Christine Vantyghem5,10, Philippe Bertolino1,2,3, Jieli Lu1,2,3,7,8, Chang Xian Zhang1,2,3,7.   

Abstract

Foxa2, known as one of the pioneer factors, plays a crucial role in islet development and endocrine functions. Its expression and biological functions are regulated by various factors, including, in particular, insulin and glucagon. However, its expression and biological role in adult pancreatic α-cells remain elusive. In the current study, we showed that Foxa2 was overexpressed in islets from α-cell-specific Men1 mutant mice, at both the transcriptional level and the protein level. More importantly, immunostaining analyses showed its prominent nuclear accumulation, specifically in α-cells, at a very early stage after Men1 disruption. Similar nuclear FOXA2 expression was also detected in a substantial proportion (12/19) of human multiple endocrine neoplasia type 1 (MEN1) glucagonomas. Interestingly, our data revealed an interaction between Foxa2 and menin encoded by the Men1 gene. Furthermore, using several approaches, we demonstrated the relevance of this interaction in the regulation of two tested Foxa2 target genes, including the autoregulation of the Foxa2 promoter by Foxa2 itself. The current study establishes menin, a novel protein partner of Foxa2, as a regulator of Foxa2, the biological functions of which extend beyond the pancreatic endocrine cells.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Foxa2; functional interaction; glucagonoma; menin; pancreatic α-cells

Mesh:

Substances:

Year:  2017        PMID: 28188614     DOI: 10.1002/path.4885

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

Review 1.  Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.

Authors:  Koen M A Dreijerink; H T Marc Timmers; Myles Brown
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

Review 2.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

3.  PGC-1β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells.

Authors:  Jia Cao; Xi Wang; Shihai Liu; Libin Wang; Danni Wang; Rong Ma; Xiaohan Li; Huimin Feng; Jia Wang
Journal:  Cancer Cell Int       Date:  2019-04-11       Impact factor: 5.722

4.  Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.

Authors:  Chaïma Cherif; Dang Tan Nguyen; Clément Paris; Thi Khanh Le; Thibaud Sefiane; Nadine Carbuccia; Pascal Finetti; Max Chaffanet; Abdessamad El Kaoutari; Julien Vernerey; Ladan Fazli; Martin Gleave; Mohamed Manai; Philippe Barthélémy; Daniel Birnbaum; François Bertucci; David Taïeb; Palma Rocchi
Journal:  Oncogene       Date:  2021-10-28       Impact factor: 9.867

5.  Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.

Authors:  Romain Teinturier; Razan Abou Ziki; Loay Kassem; Yakun Luo; Lucie Malbeteau; Samuele Gherardi; Laura Corbo; Philippe Bertolino; Thomas Bachelot; Isabelle Treilleux; Chang Xian Zhang; Muriel Le Romancer
Journal:  Breast Cancer Res Treat       Date:  2021-09-24       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.